Small Caps on the Move: Upcoming Catalysts & Critical Resistance Zones (SYRS, INBS, GUTS, PLRZ, CARM)

Every week, we ride the wave of emerging catalysts, scouting for the next small-cap superstar on the verge of a breakout. We spotlight five high-potential small-cap stocks, honing in on critical signals like resistance breakthroughs, unusual volume spikes, and consolidation patterns—steering clear of bottom-fishing traps.

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) - Syros Pharmaceuticals, Inc. saw its shares drop 10% last week, closing at $2.26. This month, the company reported its financial results for Q3, ending September 30, 2024, and shared an update on its progress. “It’s an exciting time for Syros as we approach a key milestone in establishing tamibarotene as a potential new standard for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression," said CEO Conley Chee. "We expect topline results from our pivotal SELECT-MDS-1 Phase 3 trial in mid-November. If successful, we plan to file our first New Drug Application (NDA) and launch tamibarotene in the U.S. With around 9,000 newly diagnosed HR-MDS patients each year, 50% of whom overexpress RARA, tamibarotene is well-positioned to meet a critical need, as no new frontline treatments beyond hypomethylating agents have been approved in over a decade. Our experienced team and commercial capabilities put us in a strong position to bring tamibarotene to patients.” The company highlighted an upcoming milestone: the release of pivotal CR data from the SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA gene overexpression, expected in mid-November 2024. As we await further updates, we're watching for a potential resistance break at $2.37 with increased trading volume.

--

Intelligent Bio Solutions Inc. (NASDAQ: INBS) - Intelligent Bio Solutions Inc. ended last week’s trading session at $1.39, up 2%. Recently, the company announced that its customer Mount Anvil, a prominent London-based property developer, has marked a year of enhanced workplace safety after implementing INBS’ Intelligent Fingerprinting Drug Screening Solution. This drug screening technology, adopted to boost safety and efficiency on construction sites, is used by Mount Anvil's team of approximately 220 employees and over 1,000 supply chain workers daily. Over the past year, Mount Anvil has purchased five readers and 1,750 cartridges for on-site testing. This non-invasive solution analyzes sweat from a fingerprint to detect recent drug use, delivering results within minutes without the need for specialized facilities or handling biohazardous materials. On-site testing minimizes downtime and administrative overhead, enabling immediate responses to ensure a safe work environment. Looking ahead, INBS is preparing for an FDA 510(k) submission in the fourth quarter of this year, with plans to enter the U.S. market in the first half of 2025. The company aims to tap into the growing drug screening market, which is projected to reach a Total Addressable Market of approximately $15 billion by 2030. Additionally, INBS recently partnered with B2i Digital to launch an investor-focused marketing campaign, leveraging advanced digital marketing to increase awareness of its fast, non-invasive drug screening technology. As we anticipate further updates, we’ll be watching for a potential resistance break at $1.50.

--

Fractyl Health Inc. (NASDAQ: GUTS) - Fractyl Health Inc. shares ended last week’s trading session slightly up at $2.84, a gain of nearly 1%. This month, the company announced it would present significant weight maintenance data from its Revita and Rejuva platforms at The Obesity Society's Annual Meeting, ObesityWeek 2024, held November 2-6 in San Antonio, Texas. Fractyl Health will present two significant studies at ObesityWeek 2024 in San Antonio, Texas. The first presentation, titled "Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice," is scheduled for Tuesday, November 5, 2024, from 10:45 to 11:00 a.m. CDT in Room 007 at the Henry B. Gonzalez Convention Center. The second study, "Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease," will be presented on Sunday, November 3, 2024, from 7:30 to 8:30 p.m. CDT in the Exhibit Hall at the Henry B. Gonzalez Convention Center during the Welcome Reception. Additionally, Fractyl Health will release its third-quarter 2024 financial results and provide business updates on Tuesday, November 12, at 4:30 p.m. ET. As we await further updates, we’ll be watching for a potential resistance break at $3.00, signaling possible upward momentum.

--

Polyrizon Ltd. (NASDAQ: PLRZ) - Polyrizon Ltd. shares closed last week’s trading session down 15% at $1.17. The company recently announced the completion of its underwritten initial public offering, raising $4.2 million in gross proceeds through the sale of 958,903 units at a price of $4.38 per unit. Each unit includes one ordinary share and three warrants, each allowing the purchase of an ordinary share at an initial exercise price of $4.38. Polyrizon is a development-stage biotech company focused on innovative nasal spray hydrogels that create a protective barrier in the nasal cavity to shield against viruses and allergens. Its proprietary Capture and Contain™ (C&C) technology acts as a “biological mask,” providing a hydrogel-based containment barrier. The company is further enhancing the C&C technology’s bioadhesion and retention capabilities to support intranasal drug delivery. Polyrizon's Trap and Target™ (T&T) platform, in earlier pre-clinical development, is designed to enable targeted delivery of active pharmaceutical ingredients (APIs) through nasal sprays with prolonged contact with mucosal tissue. The T&T platform, which Polyrizon plans to develop as a combination product with both a nasal sprayer and hydrogel-API formulation, is being prepared for FDA approval under the 505(b)(2) pathway. Feasibility studies for T&T products, including corticosteroids, benzodiazepines, and naloxone, are expected to begin in Q4 2024. As we await additional updates, we’re monitoring for a potential resistance break between $1.25 and $1.30.

--

Carisma Therapeutics, Inc. (NASDAQ: CARM) - Carisma Therapeutics, Inc. shares closed last week at $1.00, up 2%. Last month, the company announced an expansion of its collaboration with Moderna, Inc. (Nasdaq: MRNA) to include two newly selected targets for autoimmune disease treatment. Carisma retains rights to all autoimmune disease targets beyond these two, which are now exclusively partnered with Moderna. The partnership combines Carisma’s proprietary chimeric antigen receptor macrophage and monocyte (CAR-M) technology with Moderna’s mRNA/LNP platform to develop innovative in vivo macrophage engineering approaches for the selected autoimmune targets. Under the agreement, Carisma will receive research funding and may earn milestone payments and royalties on net sales from any resulting products. Carisma is responsible for discovery and optimization of development candidates, while Moderna will lead clinical development and commercialization. Additionally, Carisma announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, on November 8, 2024. The presentations will include preclinical efficacy data on a novel anti-GPC3 CAR-M therapy for hepatocellular carcinoma and a Phase 1 study of autologous monocytes engineered to express an anti-HER2 CAR for HER2-overexpressing solid tumors. Last week, Fintel reported that EF Hutton initiated coverage of Carisma Therapeutics with a "Buy" rating on October 30, 2024. As of October 22, 2024, Carisma’s average one-year price target is $7.75, with forecasts ranging from $6.06 to $10.50, indicating a potential 667.52% increase from the last reported closing price of $1.01. As we await further updates, we’ll be watching for a potential resistance break at $1.10 with increased trading volume.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.